# Kisspeptin Research: Mechanism, Isoforms, Fertility Trials, and Neuroendocrine Findings

> Kisspeptin mechanism of action, isoform pharmacology, IVF trigger trials, and psychosexual research — every quantitative claim cited from the peer-reviewed record.

## Overview

The Kisspeptin research literature spans three decades and four distinct domains: reproductive genetics, neuroendocrine pharmacology, fertility medicine, and psychosexual neuroscience.

## Kisspeptin mechanism of action

Kisspeptin binds KISS1R (formerly GPR54), a Gq/11-coupled GPCR expressed on hypothalamic GnRH neurons. The downstream signaling sequence: receptor activation → phospholipase C → IP3 generation → intracellular calcium release from the endoplasmic reticulum → potassium channel closure → non-selective cation channel opening → GnRH-neuron depolarization. [4]

In mouse GnRH-neuron in vitro preparations, 75% of adult neurons responded to 10 nM–1 µM KP-10 with depolarization averaging 6 mV and a firing-rate increase of 87%. Activation was prolonged: neurons remained excited for approximately 21 minutes. [4]

At the systems level, KNDy neurons in the arcuate nucleus co-express Kisspeptin, Neurokinin B (NKB), and Dynorphin A and act as the GnRH pulse generator. [15]

## Kisspeptin-10 versus kisspeptin-54

Both KP-10 and KP-54 activate KISS1R with full agonist activity at the receptor level.

**Half-life.** KP-10 plasma half-life: approximately 4 minutes in humans. KP-54 plasma half-life: approximately 27–32 minutes in humans. The roughly 8-fold difference results from KP-54's larger molecular size (6142 Da vs 1302.5 Da). [12]

**Downstream duration.** At equal molar doses IV in mice, KP-54 produced approximately 50-fold higher peak plasma levels than KP-10 and sustained LH release for 1–4 hours versus 10–60 minutes for KP-10. [12]

## Kisspeptin and fertility research

**Hypothalamic amenorrhea.** Continuous IV infusion of KP-54 at doses from 0.01 to 1.00 nmol/kg/h temporarily restored pulsatile LH secretion in women with functional hypothalamic amenorrhea. LH pulse frequency rose approximately 3-fold (Jayasena 2014, JCEM). [7]

**IVF oocyte maturation triggering.** Kisspeptin-54 (9.6 nmol/kg SC) triggered oocyte maturation in 95% of IVF patients at high OHSS risk, with a 62% live birth rate and zero OHSS cases (Abbara 2015, JCEM). [9]

**PCOS biomarker data.** A meta-analysis of nine studies (n=1,282) found serum kisspeptin levels significantly higher in PCOS patients than controls (SMD=0.57). [18]

## Does kisspeptin modulate sexual brain responses?

fMRI evidence published in 2022–2023 shows kisspeptin modulates neural processing in sexual-response networks.

In men with HSDD (n=32, double-blind crossover), kisspeptin-54 IV modulated brain activity across the sexual-response network (Cohen d = 0.81 versus placebo). Penile tumescence increased by up to 56% above placebo (Mills 2023, JAMA Network Open). [13]

In women with HSDD (n=32, double-blind crossover), kisspeptin-54 IV modulated hippocampal activity correlating with reduced sexual dysfunction distress (Thurston 2022, JAMA Network Open). [14]

## References

[1] Seminara SB, et al. The GPR54 Gene as a Regulator of Puberty. NEJM. 2003. https://www.nejm.org/doi/full/10.1056/NEJMoa035322
[4] Liu X, Lee K, Herbison AE. Kisspeptin excites GnRH neurons through a PLC/calcium-dependent pathway. Endocrinology. 2008. https://pubmed.ncbi.nlm.nih.gov/18483150/
[7] Jayasena CN, et al. Increasing LH Pulsatility in Women With Hypothalamic Amenorrhoea. JCEM. 2014. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207927/
[9] Abbara A, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation. JCEM. 2015;100(9):3322-3331. https://pubmed.ncbi.nlm.nih.gov/26192876/
[12] d'Anglemont de Tassigny X, et al. Mechanistic insights into the more potent effect of KP-54 compared to KP-10. PLoS One. 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5413024/
[13] Mills EG, et al. Effects of Kisspeptin on Sexual Brain Processing in Men With HSDD. JAMA Network Open. 2023. https://pubmed.ncbi.nlm.nih.gov/36735255/
[14] Thurston L, et al. Effects of Kisspeptin Administration in Women With HSDD. JAMA Network Open. 2022. https://pubmed.ncbi.nlm.nih.gov/36287566/
[15] Goodman RL, et al. Kisspeptin, Neurokinin B, and Dynorphin Act in the Arcuate Nucleus. Endocrinology. 2013. https://pubmed.ncbi.nlm.nih.gov/23959940/
[18] Liu H, et al. Serum kisspeptin levels in polycystic ovary syndrome. J Obstet Gynaecol Res. 2021. https://pubmed.ncbi.nlm.nih.gov/33765692/
[20] Patel AH, et al. Kisspeptin in functional hypothalamic amenorrhea. Ann NY Acad Sci. 2024. https://pubmed.ncbi.nlm.nih.gov/39287750/

---

The KISS1 record — mechanism, isoforms, and clinical trials — indexed here. Not a clinic, not a vendor.